These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
30. Donepezil: a review. Seltzer B Expert Opin Drug Metab Toxicol; 2005 Oct; 1(3):527-36. PubMed ID: 16863459 [TBL] [Abstract][Full Text] [Related]
31. Response to letter from Garcia and colleagues on cholinesterase inhibitors and Alzheimer's disease outcomes. Gillette-Guyonnet S; Andrieu S; Nourhashemi F; Reynish E; Vellas B J Gerontol A Biol Sci Med Sci; 2007 Jun; 62(6):679-80. PubMed ID: 17595427 [No Abstract] [Full Text] [Related]
32. Response to "Results, rhetoric, and randomized trials: the case of donepezil". Lisi D J Am Geriatr Soc; 2009 Jul; 57(7):1317-8; author reply 1318. PubMed ID: 19570171 [No Abstract] [Full Text] [Related]
33. How the FDA forgot the evidence: the case of donepezil 23 mg. Schwartz LM; Woloshin S BMJ; 2012 Mar; 344():e1086. PubMed ID: 22442352 [No Abstract] [Full Text] [Related]
34. Urinary incontinence: an unrecognised adverse effect with donepezil. Hashimoto M; Imamura T; Tanimukai S; Kazui H; Mori E Lancet; 2000 Aug; 356(9229):568. PubMed ID: 10950240 [TBL] [Abstract][Full Text] [Related]